Abstract
The expression and biological function of Grb2-associated binding 2 (Gab2) in renal cell carcinoma (RCC) cells was tested here. We showed that Gab2 expression was significantly elevated in human RCC tissues and RCC cells. It was correlated with over-activation of Akt and downregulation of microRNA-302c-3p (“miR-302c-3p”), a putative Gab2-targeting microRNA. Knockdown of Gab2 inhibited Akt activation and 786-O RCC cell proliferation. Reversely, forced over-expression of Gab2 led to Akt hyper-activation to facilitate 786-O cell proliferation. Exogenous expression of miR-302c caused Gab2 downregulation, Akt inhibition and 786-O cell proliferation inhibition. On the other hand, miR-302c-3p depletion by expressing its anti-sense (“antagomiR-302c”) led to Gab2 upregulation, Akt activation and increased 786-O cell proliferation. Significantly, miR-302c-3p failed to affect the proliferation of 786-O cells with shRNA-depleted Gab2. Together, we suggest that miR-302c-3p depletion in human RCC cells leads to Gab2 over-expression, Akt hyper-activation and cell proliferation.
Highlights
As a common renal cancer, renal cell carcinoma (RCC) causes large mortalities each year [1,2,3,4]
We suggest that miR-302c-3p depletion in human RCC cells leads to Grb2-associated binding 2 (Gab2) over-expression, Akt hyper-activation and cell proliferation
Gab2 over-expression correlates with miR-302c3p downregulation and Akt hyper-activation in RCC tissues and RCC cells
Summary
As a common renal cancer, renal cell carcinoma (RCC) causes large mortalities each year [1,2,3,4]. RCC’s incidence has been rising in China and around the world [1,2,3,4]. Many RCCs are diagnosed at late stages, often with local/systematic metastasis. The prognosis of RCC has been poor [1,2,3, 5, 6]. The curable surgery resection of RCC is only suitable for few patients with early-stage tumors [1, 7,8,9]. Our group [10,11,12] has been dedicated to exploring novel oncotargets for RCC
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have